Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.31 +6.5%	$2.47	$1.28 ▼ $7.85	$253.84M	1.3	1.09 million shs	1.96 million shs
GALT Galectin Therapeutics	$4.10 +5.7%	$3.00	$0.73 ▼ $4.41	$262.65M	0.82	286,838 shs	253,670 shs
HUMA Humacyte	$1.58 +2.6%	$2.23	$1.15 ▼ $7.48	$245.09M	1.9	6.29 million shs	3.56 million shs
VHAQ Viveon Health Acquisition	$11.00	$11.00	$0.00 ▼ $12.48	$62.26M	-0.1	12 shs	99 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+6.45%	-5.33%	-6.85%	+9.48%	-60.91%
GALT Galectin Therapeutics	+5.67%	+14.85%	+45.39%	+220.31%	+75.97%
HUMA Humacyte	+2.60%	-15.96%	-42.12%	-37.55%	-75.58%
VHAQ Viveon Health Acquisition	0.00%	0.00%	0.00%	0.00%	+10.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.759 of 5 stars	3.4	3.0	0.0	0.0	3.1	2.5	0.0
GALT Galectin Therapeutics	2.2531 of 5 stars	3.5	0.0	0.0	0.0	3.1	3.3	0.0
HUMA Humacyte	2.3648 of 5 stars	3.5	2.0	0.0	0.0	2.0	1.7	0.6
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.75	Moderate Buy	$12.50	441.13% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	46.34% Upside
HUMA Humacyte	3.00	Buy	$10.64	573.60% Upside
VHAQ Viveon Health Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VHAQ, HUMA, ANNX, and GALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/14/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/12/2025	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.50
8/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/23/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.81 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.86) per share	N/A
HUMA Humacyte	$818K	299.62	N/A	N/A	$0.03 per share	52.67
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.29	N/A	N/A	N/A	N/A	-70.04%	-57.67%	N/A
GALT Galectin Therapeutics	-$47.05M	-$0.64	N/A	N/A	N/A	N/A	N/A	-225.32%	N/A
HUMA Humacyte	-$148.70M	-$0.45	N/A	N/A	N/A	N/A	N/A	-78.26%	N/A
VHAQ Viveon Health Acquisition	-$610K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest VHAQ, HUMA, ANNX, and GALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/14/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	-$0.12	+$0.04	-$0.12	N/A	N/A
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	-$0.24	-$0.09	-$0.24	$0.94 million	$0.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.67	7.99
GALT Galectin Therapeutics	N/A	1.43	0.08
HUMA Humacyte	2.97	2.45	1.93
VHAQ Viveon Health Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
GALT Galectin Therapeutics	11.68%
HUMA Humacyte	44.71%
VHAQ Viveon Health Acquisition	22.14%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	11.87%
GALT Galectin Therapeutics	50.10%
HUMA Humacyte	5.10%
VHAQ Viveon Health Acquisition	75.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.89 million	96.84 million	Optionable
GALT Galectin Therapeutics	9	64.06 million	31.97 million	Optionable
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
VHAQ Viveon Health Acquisition	2	5.66 million	1.40 million	Not Optionable

VHAQ, HUMA, ANNX, and GALT Headlines

Recent News About These Companies

Viveon Health Acquisition Corp

November 21, 2024 | investing.com

Clearday, Inc. (CLRD)

September 6, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - Updated

May 3, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success

May 2, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Process

February 28, 2024 | finanznachrichten.de

VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS

February 27, 2024 | globenewswire.com

NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)

February 21, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

December 27, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)

December 22, 2023 | tmcnet.com

San Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.

November 13, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)

October 24, 2023 | finance.yahoo.com

VHAQ-R Viveon Health Acquisition Corp.

September 23, 2023 | seekingalpha.com

Viveon Health Acquisition Received Audit Opinion With Going Concern Explanation

September 15, 2023 | marketwatch.com

VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION

September 15, 2023 | finance.yahoo.com

Viveon Healthcare Increases Consideration Offered to Clearday Shareholders

September 5, 2023 | finance.yahoo.com

SPAC Viveon ups merger consideration for Clearday to $500M

August 29, 2023 | msn.com

Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement

August 29, 2023 | finance.yahoo.com

VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING

April 25, 2023 | finance.yahoo.com

Viveon Health Acquisition Corp. (VHAQ-RT)

April 18, 2023 | finance.yahoo.com

(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market

April 12, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VHAQ, HUMA, ANNX, and GALT Company Descriptions

Annexon NASDAQ:ANNX

$2.31 +0.14 (+6.45%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.30 -0.01 (-0.43%)

As of 08/22/2025 07:52 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Galectin Therapeutics NASDAQ:GALT

$4.10 +0.22 (+5.67%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.02 -0.08 (-1.95%)

As of 08/22/2025 07:59 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Humacyte NASDAQ:HUMA

$1.58 +0.04 (+2.60%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.32%)

As of 08/22/2025 07:49 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Viveon Health Acquisition NYSE:VHAQ

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time